Journal of AdvancedMedical and Dental Sciences Research

Aim: To examine the efficacy and adverse effects of Brinzolamide and Dorzolamide in patients with elevated intraocular pressure. Material and methods: Patients above 35 years of age, of any race and either sex, Diagnosed with either primary open angle glaucoma or ocular hypertension, in at least one eye, Best corrected visual acuity better than 6/24 in the study eye and The IOP in the study eye must have been considered controllable on one drug therapy in such a way that should assure clinical stability of vision and optic nerve through the trial were included in this study.Subjects were randomized using a random number table generator, into 2 groups:Group A: Received topical brinzolamide 1% monotherapy twice daily (8 am and 10 pm) for a period of three months, and Group B: Received topical dorzolamide 2% monotherapy thrice daily (8 am, 3 pm and 10 pm) for a period of three months. Results: The mean IOP after 3 weeks was 19.86 mmHg and 20.25 mmHg for the brinzolamide and dorzolamide groups respectively and after 3 months, the mean IOP was 20.53 mmHg and 20.37 mmHg in the two groups were compared, which showed that there was no statistically significant difference (p>0.05) between them, this infers that the maximum IOP lowering effect achieved within 3weeks.The incidence of ocular discomfort was significantly less in the brinzolamide group (10%) versus the dorzolamide group (30%). Conclusion: The findings of this research further demonstrate that both brinzolamide administered twice daily and dorzolamide administered three times daily resulted in a substantial and comparable reduction in intraocular pressure (IOP) in a significant proportion of individuals. For the first treatment of primary open-angle glaucoma (POAG) and ocular hypertension (OHT), we suggest using topical brinzolamide 1% as a single therapy instead of dorzolamide 2%.